American Glaucoma Society
AGS Abstracts

AGS Map About AGS Become a Member Locate a Member Near YouLinks to Resources AGS Abstracts Contact AGS AGS Home  

2002 AGS Annual Meeting

February 28 - March 3, 2002
San Juan, Puerto Rico


Search 2002 Scientific Abstracts and Posters  



  1. A Case-control Comparison of the Clinical Characteristics of Glaucoma and Ocular Hypertensive Patients With and Without the Myocilin GLN368 Stop Mutation
    Thomas A. Graul, MD

  2. Evidence for Age of Onset Heterogeneity in Adult-Onset POAG: Support for Using Phenotype Stratification in Linkage Analysis
    R.R. Allingham

    M. Good

  4. Gene Therapy Using Caspase Inhibitors Protects Optic Nerves in Experimental Rat Glaucoma
    S.J. McKinnon

  5. The Hydrolysis Of Bimatoprost In Corneal Tissue Generates A Potent Prostanoid FP Receptor Agonist
    K.M. Maxey

  6. Pilot Study on the Effects of Drying on Central Corneal Thickness
    P Challa

  7. Visual Field Loss In Glaucoma Patients With Asymmetric Peripapillary Focal Arteriolar Narrowing
    Andrew Lam

  8. Retina and Optic Nerve Oxymetry In Humans: A 1st Report Of Metabolic Measurements
    A. Harris

  9. Comparison of glaucomatous visual field defects using standard Full Threshold versus the Swedish Interactive Threshold Algorithms (SITA Standard and SITA Fast)
    Budenz DL

  10. Evaluation of a New Grading Scale for Estimating Glaucomatous Disc Damage: Comparison with HRT in Correlation with the Visual Field
    Bayer A

  11. OCT Optic Nerve Head Assessment: Comparison with HRT
    JS Schuman

  12. Retinal Nerve Fiber Layer Thickness After LASIK Measured By Optical Coherence Tomography
    Michael R. Hee, MD, PhD

  13. Individualized Compensation for Anterior Segment B
    NT Choplin

  14. Findings of the AAO/VFW Eye Screenings, 1998-2001
    Sponsel WE

  15. What Is The Risk Of Developing Pigmentary Glaucoma From PDS?
    Douglas H Johnson

  16. Population Based Prevalence Of Glaucoma In Southern India
    Alan L. Robin

  17. AFREV: A novel method of measuring functional status related to visual loss

  18. Cylindrical Tubular Structures Spanning From Trabecular Meshwork Across SC: Laboratory Studies With SEM, TEM & Tracers Correlated With Clinical Findings
    M.A. Johnstone

  19. Glaucoma Bypass Surgery: Initial Clinical Studies With The GMP Bi-Directional Glaucoma Shunt
    R. Brown

  20. Aqueous Shunt Devices in Pediatric Glaucomas Under Two Years of Age
    Beck AD

  21. Small-incision Trabeculectomy Avoiding Tenon's Capsule: 2-years Minimum Follow-up
    S. Fabian Lerner

  22. Treatment of leaking filtration blebs using needle bleb expansion and adjunctive antimetabolites: Clinical experimental evidence for an alternative theory of leaking filtration blebs
    Alfred M. Solish, MD


  1. The Role of Diurnal IOP Curves in the Management of Glaucoma Patients
    Jacob T. Wilensky, M.D.

  2. The INGOTT Indian Glaucoma Trial
    Nathan G. Congdon, M.D.

  3. Influence of Patient Data on Cup/Disc Ratio Measurement and Optic Nerve Interpretation
    Jeffrey D. Henderer, M.D.

  4. Retinal Thickness Analysis (RTA); A Paradigm shift for early glaucoma diagnosis?
    Sanjay G. Asrani, M.D.

  5. Scanning Laser Polarimetry of Edematous and Atrophic Optic Nerve Heads
    Louis R. Pasquale, M.D.

  6. Iridociliary Apposition in Plateau Iris Syndrome Remains Unchanged After Cataract Extraction
    H. Viet Tran, M.D.

  7. Does IOP in the Early Post-operative Period Predict Intraocular Pressure At One Year?
    Raul A. Chanis

  8. Failure of the Distal Plate of Double Plate Molteno Implant
    Steven R. Shields, M.D.

  9. Outcomes Of Baerveldt Glaucoma Drainage Implants In Uveitic Glaucoma
    Elizenda M. Ceballos, M.D.

  10. Rotational conjunctival pedicle flaps for the repair of exposed glaucoma drainage devices
    David G. Godfrey, M.D.

  11. Combined Cataract Extraction and Baerveldt Glaucoma Drainage Implant:  Indications and Outcomes
    Kara B. Hoffman, M.D.

  12. Risk Factors Of Hypotony Maculopathy
    Lilia A. Fannin, M.D.

  13. Risk factors for developing Tenon's capsule cysts after trabeculectomy
    Cynthia Mattox, M.D.

  14. Assessment Of Hypertensive Phase Following Ahmed Valve Implantation
    Sandra M. Johnson, M.D.

  15. Glaucoma Surgical Outcomes Study: Sight Threatening Complications of Glaucoma Surgery-Interim Results of a Pilot Study
    Henry D. Jampel, M.D.

  16. Surgical Drainage Of Choroidal Effusions
    Darrell WuDunn, M.D., Ph.D.

  17. Bleb-related infections--Presentation and outcomes of treatment for blebitis and trabeculectomy-related endophthalmitis
    Murray A. Johnstone, M.D.

  18. Short-Term Efficacy of Anti-Glaucoma Medications
    Jonathan S. Myers, M.D.

  19. Comparison of Conjunctival Inflammation and Corneal Damage Caused by Commonly Used Glaucoma Medications
    Robert J. Noecker , M.D.

  20. A Retrospective Review Of Subnormal Or Non-Response To Xalatan In Glaucomatous Eyes
    Ryan M. Rich, BS

  21. Bimatoprost and Travoprost in Clinical Practice of Glaucoma
    Alfred M. Solish, M.D.

  22. Bimatoprost as Monotherapy in Patients Previously Treated With Timolol/Latano-prost Dual Therapy
    Monte S. Dirks, M.D.

  23. Efficacy and Safety of Bimatoprost as Additive and Replacement Therapy in Patients Uncontrolled with Latanoprost
    Mei-Ju Chen, M.D.

  24. Paradoxical Intraocular Pressure Elevation after Combined Therapy with Latanoprost and Bimatoprost
    Sanjay G. Asrani, M.D.

  25. IOP, POBF, and Visual Responses to Unoprostone and Latanoprost in Open Angle Glaucoma
    William E. Sponsel, M.D.

  26. Oral NSAID Effects on Latanoprost and Brimonidine
    Sponsel WE

  27. Increased Eyelid Pigmentation Associated With Use Of Ocular Hypotensive Lipids
    Leon W. Herndon, Jr., M.D.

  28. A Study Of The IOP Lowering Efficacy Of Travatan (r) Measured Every 4 Hours Throughout A 36 Hour Period And Up To 84 Hours Following Discontinuation Of Dosing
    Harvey B. DuBiner, M.D.

  29. Safety and Pharmacokinetics of Travoprost, A Potent Prostaglandin F (FP) Receptor Agonist In Renal and Hepatic Insufficiency
    Alan L. Robin

  30. Efficacy Of Bimatoprost 0.03% As Adjunctive Therapy In Glaucoma Patients Using Latanoprost 0.005%
    Ronald E. P. Frenkel, M.D., FACS, FICS

  31. Comparative Cost Of Prostaglandin And Prostamide Therapy In Treating Patients With Elevated Eye Pressure
    Ronald E. P. Frenkel, M.D., FACS, FICS

  32. Test - Retest Reproducibility Of Retina And Optic Nerve Oxymeter Measurements In The Human Fundus
    Alon Harris, Ph.D.

  33. The Effect Of Topical Dorzolamide And Brimonidine On Retinal Capillary Blood Flow: A Crossover Study In Patients With Open Angle Glaucoma
    Ronald E. P. Frenkel, M.D., FACS, FICS

  34. A 3-Month Comparison Of Efficacy And Safety Of Brimonidine-Tartrate 0.2% / Timolol 0.5% Fixed Combination (BID) With Timolol 0.5% (BID) Or Brimonidine-Tartrate 0.2% (TID)
    E. Randy Craven, M.D.

  35. A Retrospective Comparison of Dorzolamide 2%, Topical Beta Blockers, and Brimonidine 0.2% on Intraocular Pressure After Twelve Months When Added to Latanoprost 0.005% in Glaucoma Patients
    Stanley J. Berke, M.D., FACS

::: top of page ::: abstracts 2002 ::: abstracts ::: home :::